SOHM’s India-Based Operations Expand Generic Pharmaceutical Line to Include Lifestyle Disease Drugs for Anti-Hypertension, Cardiac Disease, and Cholesterol Reduction

BUENA PARK, CA--(Marketwire - February 24, 2011) - SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced that SOHM’s India-based operations are expanding its generic pharmaceutical line to include lifestyle disease drugs for anti-hypertension, cardiac disease, and cholesterol reduction.

“India has the second largest population in the world. As the population continues to grow and with the rapid movement towards a more western lifestyle SOHM has decided this is the right time to enter the lifestyle segment of the pharmaceutical market,” stated Shailesh Shah, President and CEO of SOHM, Inc. “The lifestyle disease drug segment is the fastest growing area of India’s pharmaceutical market with the cardiac market around Rs. 5000 crore, and growing at a rate of 21% per annum. Anti-hypertensive and cardiac products like Atenolol, Amlodipin, Losartan Potassium, Ramipril and Olmesartan are the fastest growing products and cholesterol reducing agent Atorvastatin is another big growth engine within this segment. SOHM believes this area of generic pharmaceutical sales will only get larger in the future and we are preparing now to be a major distributor of lifestyle drugs in India.”

Lifestyle Disease Facts In India:

• India No.1 in cardiac patients: 10% population affected, US/Europe No. 2: 7% each; China: 4%

• Heart Diseases to be single greatest ‘killer’ in India by 2015 (WHO)

• Hypertension & Stress, especially from work, account for more than 50% of heart ailments

• 100 million people in India have high blood pressure

• Over 40% of urban Indians have high lipid levels (cholesterol and triglycerides) that are the major risk factors for heart disease

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.